Author Guidelines for British Journal of Clinical Pharmacology
- Aims and Scope
- Manuscript Categories and Requirements
- Preparing the Submission
- Editorial Policies and Ethical Considerations
- Author Licensing
- Publication Process After Acceptance
- Post Publication
- Editorial Office Contact Details
Originality of the work and agreement of all authors to submit
Papers will be considered for publication if they are relevant to any aspect of drug action in humans. Submission of a manuscript to BJCP will be taken to indicate that
- the content of the manuscript is original and that it has not been published or accepted for publication, either in whole or in part, other than on a preprint server, as a short abstract, communication or conference proceeding;
- no part of the manuscript is currently under consideration for publication elsewhere;
- all authors have seen and approved the final version of the submitted paper;
- authors have, if necessary, obtained permission to publish from their employers or institutions;
- approvals are held from any persons acknowledged, or cited as having provided personal communication; and
- permission has been obtained to use any copyrighted material, such as reproducing a figure from another article and that the source of the material has been acknowledged.
If authors have a problem contacting a co-author for approval of the final submission, the reason for this should be explained to the Editorial Office, and it may subsequently be discussed via email with the relevant Senior Editor.
If there is any overlap between a submitted manuscript of an original paper and a paper that is being submitted elsewhere, the submitting author should draw this to the Editor’s attention via the Editorial Office and provide a copy of the relevant submitted paper(s).
If there is any overlap with a paper that has already been published elsewhere, including use of the same subjects or repetition of any data, that paper must be referred to and cited in full.
For ALL papers describing investigations of human subjects (e.g. Research Papers) you must indicate which of the authors was the Principal Investigator. If the Principal Investigator is not an author of the paper, please explain why not. BJCP has a policy of not accepting papers when a person with final medical responsibility is not an author: please see the recent Editor’s View.
Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/bcp.
The submission system will prompt authors to use an ORCID iD (a unique author identifier) to help distinguish their work from that of other researchers. Click here to find out more.
Click here for more details on how to use ScholarOne.
For help with submissions, please contact the editorial office, BJCPedoffice@wiley.com.
Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology contains papers and reports on all aspects of drug action in humans: review articles, systematic reviews and meta-analyses, mini review articles, original papers, guidelines, commentaries, short reports, editorials and letters to the Editor. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment.
BJCP publishes papers describing experimental pharmacology in humans. We do not, however, normally accept papers that describe just pharmacokinetics without a measure of the pharmacodynamics of a new medicine. An example is a First-in Human study in which only pharmacokinetics and side effects are reported when quantitative pharmacodynamics could have been reported. This is described in one of our Editorials.
Original research articles are grouped under subject headings, including Clinical trials, Drug Interactions, Drug Metabolism, Drug Safety, Human Toxicology, Drugs in Pregnancy and Lactation, Methods in Clinical Pharmacology, New Drug Mechanism, Paediatric Clinical Pharmacology, Pharmacodynamics (PD), Pharmacoeconomics, Pharmacoepidemiology, Pharmacogenetics, Pharmacokinetics (PK), PK–PD relationships, Therapeutics, and Translational Research. Authors are invited on submission to suggest which heading they feel their manuscript would best fit, and may suggest additional headings if they so wish.
Investigations of human subjects are expected to have been conducted in accordance with Good Clinical Practice (GCP). GCP is an international quality standard that defines investigator responsibilities, including, among others, qualifications, resources, providing medical care to trial participants, communication with the research ethics committee, protocol, informed consent, data integrity and reporting (http://ichgcp.net/4-investigator). Everyone involved in the conduct of clinical research must be competent to perform their tasks, qualified by education, training and experience. According to GCP guidelines (or in GCP terminology) the Principle Investigator (PI) of a clinical study should be a medical doctor and that person is responsible for the execution of, and is involved in running of, the study. BJCP expects clinical studies to be conducted according to GCP guidelines and also logically expects the GCP defined PI of the study to be one of the authors.
If this is not the case for a submission, a clear statement on why the PI has not been included must be supplied with your submission.
Conflict of Interest Statement. All authors (with the exception of authors of editorials) will be asked to provide a conflict of interest statement during the submission process. See Conflicts of Interest section in Editorial Policies and Ethical Considerations for details on what to include in this section. Authors should ensure they liaise with all co-authors to confirm agreement with the final statement. Where no conflicts exist, the statement must declare ‘The authors have stated explicitly that there are no conflicts of interest in connection with this article’, and this will be published in an article in the absence of any other statement.
If your manuscript refers to unpublished data (see section below “References to data on file”), you should obtain (and provide the Editorial Office with a copy) written permission to mention a responsible individual (e.g. “Prof X...contact address email@example.com) or should identify a department in a company that can be contacted, with a contact address.
Original Research Articles
Most original research articles published in BJCP are between 3,000 and 4,000 words (for Introduction, Methods, Results and Discussion only). If you know your original research paper is going to exceed significantly 4,000 words, we require justification for this on submission.
See below (PREPARING YOUR SUBMISSION) for details on how to structure original articles. They must also contain two statements, which should be succinct, accurate and specific.
1: What is already known about this subject: In up to three short bullet point sentences (no more than 50 words), summarise the state of scientific knowledge on this subject before you did your study and say why this study needed to be done.
2: What this study adds: In up to three short bullet point sentences (no more than 50 words), give a simple answer to the questions “What do we now know as a result of this study that we did not know before?” and “What take-home message do you want to impart to readers?”
Reviews may be unsolicited, or may be commissioned by the Reviews Editor, and both can be single papers or, by prior agreement with the Reviews Editor, part of a themed issue or series. Contributors are welcome to submit single review articles directly.
Most reviews should be between 2,500 and 3,000 words, should be fully referenced, and if judged potentially suitable, will undergo full single-blind peer review. Each review should include an Abstract (unstructured) but should not contain statements on What is already known about this subject and What this study adds. Longer reviews will be considered for publication, provided they are of exceptional quality.
BJCP welcomes systematic reviews on highly original and clinically relevant subjects related to clinical and translational pharmacology. The manuscript should provide a concise but complete account of the methods used, and concentrate on highlighting key aspects of interest and relevance to clinical pharmacologists, under the following headings: Structured Abstract (Aims, Methods, Results, Conclusions), Introduction, Methods, Results, Discussion, and Conclusion.
- Introduction This should describe the background (e.g. relevant clinical and pharmacological issues) and the scope and aim of the review. The reason for the review should be stated, as well as the strengths and weaknesses of the existing literature; earlier reviews should be identified and the need for the present paper explained.
- Methods Study selection is particularly important (search strategy, type of intervention/exposure, types of studies included, types of outcomes, types of participants); include information on any data extraction and synthesis (statistical techniques and use of a quality assessment tool, if any).
- Results should comprise the key characteristics of the included studies and the main outcome measures; you should discuss variation within and between studies.
- Discussion Compare the findings with existing knowledge; outline the limitations of the review.
- Conclusion Summarise the key findings and the implications for clinical and translational pharmacology and/or practical drug therapy.
Commentaries are evidence-based opinion pieces involving areas of broad interest. No more than 1,500 words (excluding references and legends); no more than one figure or table; fewer than 10 references; no abstract or internal sectioning; no new or unreview data. Commentaries are usually invited by the Senior Editors and are often associated with articles published in the journal.
Editorials are always commissioned and are usually no more than 1,000 words. This is the only article type where you will not be asked for a Conflict of Interest statement.
Short Reports are short original articles, with a word count range of 1.500 to 2,000. The Abstract should be unstructured and comprise no more than 150 words. There should be no more than three figures and tables (in any combination). Short Reports should be structured in the same way as original articles (Introduction, Methods, Results, Discussion) and should include statements on What is already known about this subject and What this study adds.
Letters to the Editor comment on previously published papers, items of topical interest, and brief original communications. The length, including references, should not exceed 800 words, plus one figure or table; there should be no internal structuring.
Case reports must be submitted as a Letter to the Editor. They should include some novel aspect of drug action in man (for example a new adverse reaction or one that gives insight into a mechanism or method of management). Such reports may include single cases or short case series. Notes and guidelines on the format for publishing such reports, including a structured Abstract, can be found at http://www.bmj.com/content/suppl/2003/06/19/326.7403.1346.DC1.
For articles that are not open access, BJCP do not charge any page, publication or colour fees.
Themed or Special Issues and themed content (both reviews and original articles) on key topics of interest are also regularly published.
All manuscripts should be submitted in separate files: main text file; figures.
Supporting information/material should be supplied as separate files.
Cover letters are no longer required, and you will be prompted to supply all mandatory information and paperwork on submission in Scholar One.
General Style Points
The following points provide general advice on formatting and style:
- Stereoisomers. When a drug can exist as stereoisomers or diastereomers (eg geometrical isomers), the form of compound studied must be designated as follows in the methods section. In the case of racemates the prefix rac- should precede the drug name (for example rac-propranolol). When possible the absolute configuration of enantiomers should be indicated (for example (S)-warfarin). Similarly, geometrical isomerism should be indicated by the prefixes Z/E or cis/trans. When appropriate, the interpretation of data obtained using mixtures of isomers should take account of stereochemical aspects.
- Drug names. Prescribed drugs should be designated by an International Non-proprietary Name (recommended, rINN, or proposed, pINN). If such a name is not available, a drug should be designated by its British Approved Name (BAN; for example hyoscyamine) or its chemical name (for example glyceryl trinitrate). When a mixture of drugs has a combination BAN (for example co-trimoxazole, co-fluampicil), that should be used.
For brevity, a company's code name may be used, but in that case the full chemical name or a figure showing the structure of the drug should be given in the introduction or a reference provided that gives this information.
Some mediators with well-established common names (e.g. prostacyclin) are also prescribed as licensed preparations with an rINN (e. g. epoprostenol). In such cases the rINN should be used in the context of therapeutic use. Sometimes English and American usage varies, as with adrenaline / epinephrine and noradrenaline / norepinephrine. “Adrenaline / noradrenaline” relate clearly to terms such as “noradrenergic”, “adrenergic” and “adrenal gland” but we will accept the term preferred by authors.
- Symbols. A set of standard symbols in pharmacokinetics and pharmacodynamics can be found here.
- Abbreviations. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Articles should not include an abbreviations section. Each abbreviation must be defined at first use, either in the text, in a figure or table, or in their associated legends.
- Numbers. Under 10 are spelled out, except for measurements with a unit (8mmol/l), age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).
- Units. SI units (mass or molar units) should be used. If other units are used, a conversion factor should be included in the Methods section. Solidus should be avoided as far as possible and the negative index used instead, e.g. mg kg-1 rather than mg/kg.
Research articles: Author Checklist
The text file should be presented in the following order:
i. Title (including PI’s name)
ii. Short running title of less than 40 characters
iii. The full names of all authors
iv. The authors’ institutional affiliations (ie where the work was carried out, with a footnote for an author’s present address if different from where the work was carried out)
v. Abstract and keywords
vi. Main text:
- Structured Summary
- Statement1: What is already known about this subject (up to three bullet points)
- Statement 2: What this study adds (up to three bullet points)
ix. Tables (each table complete with title and footnotes)
x. Figure legends
xi. Appendices (if relevant).
xii. Word count (excluding the title page, summary, references, legends to tables, and legends to figures).
Figures must be submitted as separate files.
Title. The title should be short and informative, containing major keywords related to the content. The title should not contain abbreviations (see Wiley's best practice SEO tips) and should not exceed 150 characters.
The Abstract should be divided into the following sections: 'Aims', 'Methods, ‘Results' and 'Conclusions'; it should not exceed 250 words. It should include estimates of relevant treatment effects, along with 95% CIs or other measures of variability, when appropriate, and confidence intervals (CI) of relevant differences between major end points.
Please provide three to five keywords from the list provided in Scholar One.
The journal uses British spelling; however, authors may submit using either option, as spelling of accepted papers is converted during the production process. Be clear and concise; avoid jargon and neologisms. You should include details of precision, accuracy, sensitivity, and specificity for drug/metabolite assays.
Acknowledgements. Contributions from individuals who do not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate. All support, financial or otherwise, for any work described should be acknowledged, with the exception of support from employing institutions identifiable from the title page. This includes CRO contributions to any trials, and support with medical writing, for PK, PD and statistical analysis. Authors are reminded that if they want to acknowledge the assistance of an individual, it is courteous to ask the individual’s permission to do so.
References should be cited using the Vancouver style.
All references should be numbered consecutively in order of appearance and should be as complete as possible. In-text citations should be numbers in square brackets e.g. , , etc. Journal titles are abbreviated; abbreviations may be found in the following: MEDLINE , Index Medicus , or CalTech Library
Submissions are not required to reflect the precise reference formatting of the journal (use of italics, bold etc.); however, it is important that all key elements of each reference are included. Please see below for examples of reference content requirements.
For more information, please see the Vancouver Reference Style Guide.
- Wood WG, Eckert GP, Igbavboa U, Muller WE. Statins and neuroprotection: a prescription to move the field forward. Ann N Y Acad Sci 2010; 1199:69-76.
- Hoppert, M. Microscopic techniques in biotechnology. Weinheim: Wiley-VCH; 2003.
- Cancer-Pain.org [homepage on the internet]. New York: Association of Cancer Online Resources, Inc.; c2000–01 [Cited 2015 May 11]. Available from: http://www.cancer-pain.org/.
- Brown, LJ; Year. Dataset title; Data repository or archive; Version (if any); Persistent identifier (e.g. DOI).
References to data on file:
Any assertions within a submitted manuscript that are backed up by reference to unpublished data should be clearly noted as such in the body of the manuscript and should give a clear direction to the reader as to how they might request this data: e.g. ‘ACME34178 is not metabolised by CYP3A4 (unpublished data on file, ACME Drug Co. Ltd., Didcot, UK)’, ‘Drug Z is known to partition extensively into erythrocytes (personal communication from Prof. X, University of Y)’. If making such a reference to unpublished data the author should obtain (and provide the Editorial Office with a copy) written permission to mention an individual (Prof X) or should identify a department in a company that can be contacted with an address (Department of Drug Metabolism, ACME Drug Co, firstname.lastname@example.org) and the permission should come from the head of that department or their designate.
Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.
Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.
Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted. Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.
Figures submitted in colour are reproduced in colour online free of charge. Please note, however, that it is preferable that line figures (e.g. graphs and charts) are supplied in black and white.
Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.
Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc. Click here for the Publisher’s FAQs on supporting information.
Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.
Wiley Author Resources
Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimisation.
Editing, Translation, and Formatting Support: Wiley Editing Services can greatly improve the chances of a manuscript being accepted. Offering expert help in English language editing, translation, manuscript formatting, and figure preparation, Wiley Editing Services ensures that the manuscript is ready for submission.
Publication on preprint servers
The journal will consider for review articles previously available as preprints on non-commercial servers such as bioRxiv, psyArXiv, SocArXiv, etc, as long as authors have retained copyright of their articles during the preprint process. Authors may also post the submitted version of their manuscript to non-commercial servers at any time. Authors should update any pre-publication versions with a link to the final published article. Allowing submission under such circumstances does not, of course, guarantee that an article will be sent out for review to that it will be accepted for publication in BJCP.
Editorial Review and Acceptance
The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Except where otherwise stated, manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Senior Editors determine that the paper meets the appropriate quality and relevance requirements.
The journal’s policy on confidentiality of the review process is available here.
Correspondence related to published research in BJCP is not usually subject to peer review, but is shared with the authors of the original paper prior to any publication, with a right to reply. All substantive papers — ie original research and reviews (commissioned and non-commissioned), including those published under our open access programme OnlineOpen — undergo the same rigorous and consistent peer review process.
Once submitted, a manuscript will first be checked by the Editorial Office to ensure all elements have been submitted. If any required documentation is not present, the Editorial Office will return the manuscript to the authors and request any missing information or material.
Once a paper is accepted, it is published within a few days on the journal website in the format of the final accepted version, i.e. as a PDF of the Word version. This final accepted version, known as an ‘Accepted Article’ is fully citable (and has a perpetual Digital Object Identifier [DOI]). Accepted articles are replaced by Early View (see below) and then the final version of record once published in an issue.
Editorial Review and Transfer to Other British Pharmacological Society (BPS) journals
Pharmacology Research & Perspectives (PR&P), an open access journal, is jointly edited on behalf of the BPS and the American Society of Pharmacology and Experimental Therapeutics (ASPET). The BPS also publishes British Journal of Pharmacology (BJP).
The Senior Editors of BJCP might consider that a submitted manuscript is out of scope and more suitable for consideration by BJP or PR&P. If so, the Editors will offer authors the opportunity to transfer their manuscript to the Editorial office of its sister journals for consideration.
Authors can, if they choose, facilitate the review process by providing, as part of the submission process, the names, institutions and institutional email addresses of up to two suggested reviewers, on the understanding that the Editors are not bound by any such nomination, and that the Editors will check the credentials of these nominated individuals carefully to ensure optimum ethical standards. Opposed reviewers may also be supplied.
Human Studies and Subjects
For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice. Details should be given in the methods section.
Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author licence to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.
If the person is a minor, consent must be obtained from the child’s parents or guardians. If the person is deceased, it is both essential and ethical to obtain consent for use from the next of kin. If this is impractical you need to balance the need to use the photo against the risk of causing offence. In all cases ensure you obscure the identity of the deceased. If using older material, or for material obtained in the field, for which signed release forms are, for practical purposes, unobtainable, you will need to confirm in writing that the material in question was obtained with the person’s understanding that it might be published.
Clinical Trial Registration
The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.
Research Reporting Guidelines
Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. Authors are encouraged to adhere to the following research reporting standards, where applicable.
- STARD and TRIPOD
- the EQUATOR Network
- Future of Research Communications and e-Scholarship (FORCE11)
- ARRIVE guidelines
- National Research Council's Institute for Laboratory Animal Research guidelines:
- The Gold Standard Publication Checklist from Hooijmans and colleagues
- Minimum Information Guidelines from Diverse Bioscience Communities (MIBBI) website
- Biosharing website
- REFLECT statement
The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.
Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/
The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:
1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
2. Been involved in drafting the manuscript or revising it critically for important intellectual content;
3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.
Additional Authorship Options: Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’
It is the authors’ sole responsibility to obtain permission to use copyrighted material in a paper, in advance of submission and to acknowledge fully the source of the material.
As part of the journal’s commitment to supporting authors at every step of the publishing process, the journal requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around just two minutes to complete. Find more information here.
This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read the Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found at authorservices.wiley.com/ethics-guidelines/index.html.
Appealing Editorial Decisions
An author may appeal an editorial decision by directly contacting the Editor-in-Chief through the Editorial office.
- An appeal will override an earlier decision only when new information becomes available (for example, additional factual input by the authors, revisions, extra material in the manuscript, or appeals about conflicts of interest and concerns about biased peer review).
- The Editor-in-Chief will mediate all exchanges between authors and peer reviewers during the appeal.
- The Editor-in-Chief's decision following an appeal is final.
- If the Editor-in-Chief has a conflict of interest and cannot review the appeal, this will be delegated to an independent Senior Editor.
If a paper is accepted for publication, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright licence agreement on behalf of all authors of the paper.
Authors may choose to publish under the terms of the journal’s standard copyright agreement, or OnlineOpen under the terms of a Creative Commons Licence.
General information regarding licensing and copyright is available here. To review the Creative Commons Licence options offered under OnlineOpen, please click here. (Note that certain funders mandate a particular type of CC licence be used; to check this please click here.)
Self-Archiving Definitions and Policies: Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please click here for more detailed information about self-archiving definitions and policies.
Open Access fees: Authors who choose to publish using OnlineOpen will be charged a fee. A list of Article Publication Charges for Wiley journals is available here.
Funder Open Access: Please click here for more information on Wiley’s compliance with specific Funder Open Access Policies.
Linking to the BPS/IUPHAR Guide to Pharmacology
Nomenclature used in your article should follow that of the BPS/IUPHAR Guide to Pharmacology. Should your manuscript be accepted, for all key ligands and targets cited in your manuscript, you will be asked to add links (within the body of the text, at first mention) from your article to the Guide to Pharmacology. You will be asked by the Editorial office to also provide a list of these hyperlinked ligands and targets. This list will be for checking purposes only, by the journal copy editors. You will be given clear instructions on how to carry out this requirement, but you can also find instructions here.
Accepted Article Received in Production
When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license at this point.
The journal offers Wiley’s Accepted Articles service for all manuscripts. This service ensures that accepted ‘in press’ manuscripts are published online shortly after acceptance, prior to copy-editing or typesetting. Accepted Articles are published online a few days after final acceptance and appear in PDF format only. They are given a Digital Object Identifier (DOI), which allows them to be cited and tracked and are indexed by PubMed. After the final version article is published (the article of record), the DOI remains valid and can still be used to cite and access the article.
Accepted Articles will be indexed by PubMed; submitting authors should therefore carefully check the names and affiliations of all authors provided in the cover page of the manuscript so it is accurate for indexing. Subsequently, the final copyedited and proofed articles will appear in an issue on Wiley Online Library; the link to the article in PubMed will update automatically.
Once the paper is typeset, the author will receive an email notification with the URL to download a PDF typeset page proof, as well as associated forms and full instructions on how to correct and return the file.
Please note that the author is responsible for all statements made in their work, including changes made during the editorial process – authors should check proofs carefully. Note that proofs should be returned within 72 hours from receipt of first proof.
Once proofs have been corrected the paper will be published online in the next available issue. The online version is definitive and there will be no further opportunity for correction. The date of publication of the article is the date of its first appearance online as an Accepted Article.
The journal offers rapid publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online, as Editors also need to review proofs. Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.
A video abstract can be a quick way to make the message of your research accessible to a much larger audience. In 2017, Wiley, our Publishers, and its partner Research Square, will be offering, on a trial basis, a service of professionally produced video abstracts, available to authors of 5 articles selected by the journal. You can learn more about it at www.wileyauthors.com/videoabstracts. Authors of papers selected for this service will be contacted through the editorial office.
Access and Sharing
When the article is published online:
- The author receives an email alert (if requested).
- The link to the published article can be shared through social media.
- The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
- The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the article.
Full information for authors on sharing content can be found here.
Print copies of the article can be ordered (instructions are sent at proofing stage or contact email@example.com.
Promoting your article
To find out how to best promote an article, click here.
Measuring the impact of an article
Author Guidelines updated 19th October 2017
Download the App
New Android App Available!
iOS App for iPad or iPhone